Biomarkers of cetuximab resistance in patients with head and neck squamous cell carcinoma

Objective: In patients with head and neck squamous cell carcinoma (HNSCC), cetuximab [a monoclonal antibody targeting epidermal growth factor receptor (EGFR)] has been shown to improve overall survival when combined with radiotherapy in the locally advanced setting or with chemotherapy in first-line...

Descripción completa

Detalles Bibliográficos
Autores principales: Leblanc, Olivia, Vacher, Sophie, Lecerf, Charlotte, Jeannot, Emmanuelle, Klijanienko, Jerzy, Berger, Frédérique, Hoffmann, Caroline, Calugaru, Valentin, Badois, Nathalie, Chilles, Anne, Lesnik, Maria, Krhili, Samar, Bieche, Ivan, Le Tourneau, Christophe, Kamal, Maud
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Compuscript 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7142836/
https://www.ncbi.nlm.nih.gov/pubmed/32296588
http://dx.doi.org/10.20892/j.issn.2095-3941.2019.0153

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7142836/
https://www.ncbi.nlm.nih.gov/pubmed/32296588
http://dx.doi.org/10.20892/j.issn.2095-3941.2019.0153

Ejemplares similares